DOCSLIB.ORG

Corporate Governance

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Corporate Governance Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 76 Our Board 78 Our Corporate Executive Team 82 Responsible leadership 84 Division of responsibilities 90 Composition, succession and evaluation 92 Nominations Committee report 92 Audit, risk and internal control 96 Audit & Risk Committee report 96 Science Committee report 107 Corporate Responsibility Committee report 109 Section 172 statement 111 Directors’ report 113 GSK Annual Report 2019 75 Chairman’s Governance statement I am pleased to present our Corporate Governance report for 2019 and an overview of the changes to our governance arrangements for 2020 as we work towards separation of the Group. Last year was an important one for GSK. The Board led by Board governance and architecture Sir Philip Hampton and Emma re-set the strategic direction Given the company is embarking on a period of transition and of the company. I was honoured to have the opportunity to join the last two years in particular have been a period of significant the Board and lead it through the separation to create two new change from a Board and senior executive perspective, we world-class businesses. I was particularly excited to work with decided to undertake an external review to gather the views of Emma. She has brought real clarity to decision making, where a both the Board and CET members to ready us for the task pharma veteran might have been less dispassionate. She has ahead. This review, together with the insights from my also attracted the best in the industry to form her top team. introductory meetings with investors and feedback from the The Board is focused on supporting her and management in employees I have met since joining, has helped us to further transforming the Group and executing our strategy. refine our Board governance and architecture. This will help At the beginning of this important journey for the company and focus and facilitate the Board’s work in support of management, for my tenure at GSK, it was helpful that my first Board meeting to be as effective and efficient as possible in delivering the in September last year included a joint Board and CET Strategy transformation of the Pharmaceuticals and Vaccines business offsite session. Together, we were able to consider the next and the separation of the Consumer Healthcare business. steps for our plans and the way forward. This was a great start. A description of the review process which was carried out by My understanding of GSK has been informed by a robust Jan Hall of No 4 (No 4) follows this statement. induction process, designed by Emma and our Company After the review, the Board agreed its critical objectives for the Secretary, introductory meetings with our investors and the next three years towards separation. The Board then considered Board review we decided to commission. how best to distribute the workload between it and its Induction Committees to ensure optimal effectiveness. The Board will I was keen to learn more about GSK, and started by also increase the time it spends on science given the understanding R&D from Hal and visiting our R&D sites in the importance of the strengthening the pipeline. US and UK, including Tesaro, and meeting with 23andMe, with It was agreed that once the Board has conducted its annual whom we have an important collaboration. I look forward to review into the Group’s enterprise risks, deeper enterprise visiting more of the Group in due course. risk oversight should be undertaken by the Board Committee Since joining, I have met on an individual basis with Board and which focuses on that aspect of the business most closely. CET members and other key executives. I have also attended Enhancements were also considered to the ways of working meetings of each of our Board Committees to assess and and governance architecture of the Board’s Committees. understand our Board culture and dynamics, and the company’s These included: corporate governance arrangements. Audit & Risk Committee (ARC) Introductory meetings with investors The ARC will continue to have a strong focus on financial I wanted to hear what our shareholders think of GSK. I have reporting, as well as monitoring the dashboard of all GSK’s held over 20 meetings with a range of investors making up enterprise risks and the process by which they are identified approximately 30% of our register. They comprised a mix of our and prioritised as part of its oversight of our internal control top UK and US shareholders, plus other key investors. I also led framework. It will conduct the detailed reviews of GSK’s our Annual Governance Meeting in December 2019. I have Financial controls and reporting, Anti-bribery and corruption, noted the following points: Commercial practices, Privacy and Information security enterprise risks, as well as receiving business unit risk reports – Clear support for Emma – Demonstrate pipeline progress on Pharmaceuticals, Vaccines, Consumer Healthcare and our and Hal, and the top team ahead of separation Global Support functions. In addition, it will be responsible for – Support for the separation – Managing capital allocation, debt, oversight of the financial components as we work towards of the Group dividend and business development separation. – Positive progress on – Evidence of a positive shift in our Innovation to date performance culture and our R&D culture has been transformed 76 GSK Annual Report 2019 Strategic report Governance and remuneration Financial statements Investor information Nominations Committee The Board is mindful that the Financial Reporting Council’s The remit of the Nominations Committee will be expanded (FRC) 2018 UK Corporate Governance Code (2018 Code) to encompass Corporate Governance matters, therefore freeing indicates that Non-Executive Directors should not serve for more time at the Board. The Committee will be renamed the more than nine years. However, the Board considers this is the Nominations & Corporate Governance Committee. All Non- most appropriate way to proceed in the long-term best interests Executives will be invited to participate in meetings of the of shareholders and believes, following a rigorous review, that Committee when it considers succession and talent. Judy continues to act with utmost independence, despite her Transformation & Separation Committee length of tenure. A Transformation & Separation Committee will be established The Nominations Committee continues to oversee succession to support and advise management’s work on transforming planning for the Board and the CET. In due course, it will and separating the Group. I will chair this Committee whose consider the needs of the post separation boards. members will include our Senior Independent Director (SID) Non Executive Directors fees and the Chairs of the ARC, Remuneration and Corporate We have reviewed our Non-Executive Directors’ fee Responsibility Committees. It will meet as required and it is arrangements as part of our three year remuneration policy expected that it will be more active as we near separation. review. Our Non-Executive Director fees were last increased R&D at the Board & Science Committee in 2013 and, following a review, we concluded that it was Given the critical importance of strengthening the pipeline, appropriate to make increases to the fees to bring them into line the Board will increase its time spent on R&D strategy, while the with our comparator group. We have also taken the opportunity Science Committee will focus on science at a deeper level to to update our policy to be able to remunerate our Workforce further support the Board’s understanding and provide Engagement Director, for the considerable work she undertakes reassurance and guidance as required. as part of this new and expanding role. The investors we The Science Committee will then have three broad objectives: consulted on these changes were supportive of them. Full the scientific assumptions driving our strategy, technical details can be found on page 140. assurance, and risk oversight. It will support the Board in its I can confirm that during 2019 the company complied with the understanding of our agreed R&D strategy and of any external requirements of the 2018 Code. A copy of the 2018 Code can transactions by performing a deep review of the underlying be found on www.frc.org.uk. scientific assumptions. In addition, it will have oversight of I commend this report to all our stakeholders. R&D’s enterprise and other significant risks. The Board feels that with these enhancements to our governance it will improve further our effectiveness and support Sir Jonathan Symonds us through the separation process. Chairman Succession planning 3 March 2020 My first task as Nominations Committee Chair has been to focus on the search for Judy’s successor as Chair of the ARC. We have made good progress to date and look forward to announcing the conclusion of our search. We considered the ideal transition for this important role. We are very pleased that Judy has confirmed that she will stay on the Board for a further year, despite having served over nine years, and she will now step down from the Board at the 2021 Annual General Meeting. This should facilitate a smooth transition. Judy will continue as its Chair until the 2020 Annual Report is completed, when her successor will then Chair the ARC. GSK Annual Report 2019 77 Our Board Board governance and architecture The Board carries out an evaluation of its performance and There is full commitment from the Board as a whole to support that of its Committees every year. The evaluation is normally the overarching strategy of creating two great companies. facilitated externally every third year. The last external evaluation The Board is confident that the CET is focused on driving was facilitated two years ago by Ffion Hague of Independent performance over the next three years.
Load more

Recommended publications
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* GENOCEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 372427 10 4 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 30, 2015 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    [Show full text]
  • Corporate Governance
    Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 78 The Board 80 Corporate Executive Team 83 Board architecture 85 Board roles and responsibilities 86 Board activity and principal decisions 87 Our purpose, values and culture 90 The Board’s approach to engagement 91 Board performance 94 Board Committee information 96 Our Board Committee reports 97 Section 172 statement 108 Directors’ report 109 GSK Annual Report 2020 77 Chairman’s Governance statement In last year’s Governance statement, I explained that our primary Education and focus on Science objective for 2020 was to ensure there was clarity between the Given the critical importance of strengthening the pipeline, Board and management on GSK’s execution of strategy and its the Board has benefitted from devoting a higher proportion of operational priorities. We have aligned our long-term priorities its time in understanding the science behind our strategy and of Innovation, Performance and Trust powered by culture testing its application. It is important that the Board has a and agreed on the metrics to measure delivery against them. working understanding of the key strategic themes upon The Board’s annual cycle of meetings ensures that all major which our R&D strategy is based. These themes have been components of our strategy are reviewed over the course complemented by Board R&D science thematic deep dives. of the year. Our focus was on the fundamentals of our strategy: human The COVID-19 pandemic impacted and dominated all our genetics, the immune system and AI and ML, as well as to lives for the majority of 2020.
    [Show full text]
  • Governance and Remuneration 2014
    Governance & remuneration reportStrategic In this section Our Board 72 Our Corporate Executive Team 76 Chairman’s letter 78 Corporate governance framework 79 Board report to shareholders Oversight and stewardship in 2014 and future actions 80 remuneration & Governance Leadership and effectiveness 82 Committee reports Audit & Risk 86 Nominations 92 Corporate Responsibility 94 Remuneration report Chairman’s annual statement 96 Annual report on remuneration 97 2014 Remuneration policy report 119 Financial statements Financial Investor information Investor GSK Annual Report 2014 71 Our Board Strategic reportStrategic Diversity Experience International experience Composition Tenure (Non-Executives) % % % % Scientific 19 Global 75 Executive 19 Up to 3 years 39 % % % % Finance 31 USA 100 Non-Executive 81 3-6 years 15 % % % % Industry 50 Europe 94 Male 69 7-9 years 23 % % % EMAP 63 Female 31 Over 9 years 23 Sir Christopher Gent 66 Skills and experience Chairman Sir Christopher has many years of experience of leading global businesses and a track record of delivering outstanding performance Governance & remuneration & Governance Nationality in highly competitive industries. He was appointed Managing Director British of Vodafone plc in 1985 and then became its Chief Executive Officer Appointment date in 1997 until his retirement in 2003. Sir Christopher was also a 1 June 2004 and as Chairman Non-Executive Director of Ferrari SpA and a member of the British on 1 January 2005 Airways International Business Advisory Board. Committee membership External appointments Corporate Responsibility Sir Christopher is a Senior Adviser at Bain & Co. Committee Chairman, Nominations, Remuneration and Finance Sir Philip Hampton 61 Skills and experience Chairman Designate Prior to joining GSK, Sir Philip chaired major FTSE 100 companies including J Sainsbury plc.
    [Show full text]
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • United States Securities and Exchange Commission
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6*) THERAVANCE BIOPHARMA, INC. (Name of Issuer) Ordinary Shares, par value, $0.00001 (Title of Class of Securities) G8807B106 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 17, 2020 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
    [Show full text]
  • GSK/Novartis Shareholder Circular and Notice of Meeting
    THIS DOCUMENT AND ANY ACCOMPANYING DOCUMENTS ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action you should take, you are recommended to seek your own financial advice immediately from your stockbroker, bank manager, fund manager, solicitor, accountant or other appropriate independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (“FSMA”) if you are resident in the United Kingdom or, if not, from another appropriately authorised independent financial adviser. This document is a circular relating to the Transaction which has been prepared in accordance with the Listing Rules and approved by the Financial Conduct Authority (“FCA”). If you sell or have sold or otherwise transferred all of your Ordinary Shares, please forward this document, together with the accompanying documents as soon as possible to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected, for delivery to the purchaser or the transferee. If you sell or have sold or otherwise transferred only part of your holding of Ordinary Shares, you should retain this document and the accompanying documents and consult with the bank, stockbroker or other agent through whom the sale or transfer was effected as to the action you should take. Any person (including, without limitation, custodians, nominees, and trustees) who may have a contractual or legal obligation or may otherwise intend to forward this document to any jurisdiction outside the United Kingdom should seek appropriate advice before taking any such action. The distribution of this document and any accompanying documents into jurisdictions other than the United Kingdom may be restricted by law.
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 2015 saw substantial progress to accelerate new product sales growth and strengthen our Pharmaceuticals, Vaccines and Consumer Healthcare businesses Overview of 2015 Strategic report “ In 2015, we made substantial progress to accelerate new product sales growth, integrate new businesses in Vaccines and Consumer Healthcare and restructure our global Pharmaceuticals business. This progress means the Group is well positioned to return to core earnings growth in 2016.” Sir Andrew Witty, Chief Executive Officer Governance & remunerationPerformance Financial statements summary Investor information £23.9bn £10.3bn £5.7bn £3.9bn Group turnover Total operating profit Core operating profit Cash dividends paid (up 6% CER/up 1% CER (up >100% CER) a (down 9% CER/down 3% in 2015 pro-forma) a CER pro-forma)a £2.0bn 174.3p 75.7p 10 0 % New product sales b Total earnings per share Core earnings per share Markets now operating (up >100%) (up >100%, primarily (down 15% CER, primarily new commercial model reflecting impact of reflecting short-term dilution transaction gains) of the Novartis transaction)a ~40 20 ~13 % 1st Potential new medicines Potential to file up to Estimated internal In Access to Medicine and vaccines profiled at R&D 20 assets with regulators rate of return in R&D Index event, 80% of which have by 2020 in 2015 potential to be first-in-classc Footnotes a We use a number of adjusted measures to report the performance of our business, as described on page 54. These include core results, CER growth rates and pro-forma CER growth rates. A reconciliation of total results to core results is set out on page 62.
    [Show full text]
  • GSK Delivers Q2 Sales of £7.6 Billion -2% AER, -3% CER (Pro-Forma -10% CER*) Total EPS 45.5P >100% AER; >100% CER; Adjusted EPS 19.2P -37% AER, -38% CER
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020 Commission File Number 001-15170 GlaxoSmithKline plc (Translation of registrant's name into English) 980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F . .X. Form 40-F . Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ Issued: Wednesday, 29 July 2020, London U.K. GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*) Total EPS 45.5p >100% AER; >100% CER; Adjusted EPS 19.2p -37% AER, -38% CER Financial and product highlights ● Reported Group sales £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*; -8% CER excluding divestments/brands under review). Pharmaceuticals £4.1 billion -5% AER, -5% CER; Vaccines £1.1 billion -29% AER, -29% CER; Consumer Healthcare £2.4 billion +25% AER, +25% CER (Pro-forma -6% CER) ● H1 Reported group sales £16.7 billion 8% AER, 8% CER (Pro-forma flat CER*; +1% CER excluding divestments/brands under review) ● Sales decline in Q2 2020 reflects expected disruption from COVID-19, particularly in Vaccines as well as destocking from Q1 2020 in Pharmaceuticals and Consumer Healthcare ● Total Respiratory sales £883 million +17% AER, +16% CER.
    [Show full text]
  • Annual Report 2017
    Annual Report Image HIV virus 2 017 GSK Annual Report 2017 GSK is a science-led global healthcare company In the Strategic report Our new CEO discusses Measuring performance 2017 performance and our and managing risk new long-term priorities See pages 05–07 See pages 18–21 How we create Innovation and Performance long-term value in each of our three businesses See pages 08–09 See pages 22–41 Industry trends How our three businesses together contribute to our Trust priority See pages 10–11 See pages 42–51 Our new long-term priorities: Financial review Innovation, Performance and Trust See pages 12–17 See pages 52–78 Cover image Cautionary statement 30 years after developing the first HIV See the inside back cover of this document medicine, our research into treatment and for the cautionary statement regarding prevention of HIV continues. We remain forward-looking statements. at the forefront of helping people living with HIV, driving innovation and working with communities all over the world. 01 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Our financial performance in 2017a £30.2bn AER +8% £6.7bn AER +51% Group turnover CER +3% New product salesb CER +44% £4.1bn AER +57% £8.6bn AER +12% Total operating profit CER +39% Adjusted operating profit CER +5% 31.4p AER +67% 111.8p AER +11% Total earnings per share CER +36% Adjusted earnings per share CER +4% £6.9bn £3.4bn £3.9bn 80p Net cash flow from Free cash flow Dividends declared 2017 dividend operating activities for 2017 per
    [Show full text]
  • Vote Summary Report Reporting Period: 07/01/2018 to 06/30/2019 Institution Account(S): Epoch Global Shareholder Yield Fund
    Vote Summary Report Reporting Period: 07/01/2018 to 06/30/2019 Institution Account(s): Epoch Global Shareholder Yield Fund Nutrien Ltd. Meeting Date: 07/19/2018 Country: Canada Primary Security ID: 67077M108 Record Date: 06/06/2018 Meeting Type: Annual Ticker: NTR Primary CUSIP: 67077M108 Primary ISIN: CA67077M1086 Primary SEDOL: BDRJLN0 Vote Proposal Votable Vote Against Number Proposal Text Proponent Proposal Mgmt Rec Instruction Mgmt 1.1 Elect Director Christopher M. Burley Mgmt Yes For For No 1.2 Elect Director Maura J. Clark Mgmt Yes For For No 1.3 Elect Director John W. Estey Mgmt Yes For For No 1.4 Elect Director David C. Everitt Mgmt Yes For For No 1.5 Elect Director Russell K. Girling Mgmt Yes For For No 1.6 Elect Director Gerald W. Grandey Mgmt Yes For For No 1.7 Elect Director Miranda C. Hubbs Mgmt Yes For For No 1.8 Elect Director Alice D. Laberge Mgmt Yes For For No 1.9 Elect Director Consuelo E. Madere Mgmt Yes For For No 1.10 Elect Director Charles "Chuck" V. Magro Mgmt Yes For For No 1.11 Elect Director Keith G. Martell Mgmt Yes For For No 1.12 Elect Director A. Anne McLellan Mgmt Yes For For No 1.13 Elect Director Derek G. Pannell Mgmt Yes For For No 1.14 Elect Director Aaron W. Regent Mgmt Yes For For No 1.15 Elect Director Mayo M. Schmidt Mgmt Yes For For No 1.16 Elect Director Jochen E. Tilk Mgmt Yes For For No 2 Approve Re-appointment of KPMG LLP as Mgmt Yes For For No Auditors 3 Approve Stock Option Plan and Grant of Stock Mgmt Yes For For No Options 4 Advisory Vote on Executive Compensation Mgmt Yes For For No Approach
    [Show full text]
  • Chairman-Statement-2021-Final.Pdf
    GSK 2021 Annual General Meeting Sir Jonathan Symonds, Chairman Welcome and introduction Good afternoon ladies and gentlemen and welcome to our twenty-first AGM. I am Sir Jonathan Symonds, Chairman of GlaxoSmithKline plc. I am pleased that so many of you have been able to join us today via the Lumi AGM website, telephone or Zoom. It is important in these challenging times to make the experience as close of a “traditional” AGM as possible. I hope we succeed. It is now just after 2.30pm. I can confirm that a quorum is present here at GSK House and I declare the AGM open. I would like to introduce my fellow Board members who are physically present with me today here at GSK House – appropriately socially distanced of course. On my left is Emma Walmsley, our CEO. To the far left is Iain Mackay our CFO, and next to me on my right is our Company Secretary, Victoria Whyte. Due to COVID restrictions, the rest of our Board is joining electronically. I would like to introduce them to you: Dr Hal Barron, our Chief Scientific Officer & President of R&D; Vindi Banga, our Senior Independent Director; Vivienne Cox, Workforce Engagement Director; Lynn Elsenhans, Chair of our Corporate Responsibility Committee; Jesse Goodman, Chair of our Science Committee and a Scientific and Medical Expert; Urs Rohner, Chair of our Remuneration Committee; Laurie Glimcher, a Scientific and Medical Expert; Charlie Bancroft, recently appointed Chair of our Audit & Risk Committee. Finally, Judy Lewent, until recently Chair of our Audit & Risk Committee. Judy is stepping down from the Board at the conclusion of this meeting having served 10 years.
    [Show full text]
  • Do More, Feel Better, Live Longer Annual Report 2012 B GSK Annual Report 2012
    Do more, feel better, live longer Annual Report 2012 b GSK Annual Report 2012 Our mission Notice regarding limitations on Director Liability under English Law At GSK our mission is to Under the UK Companies Act 2006, a safe harbour limits the liability of Directors in respect of statements in and omissions from the Report of the Directors contained on pages 1-136 and 239-244 which includes a business improve the quality of review on pages 1 to 86. Under English law the Directors would be liable to the company, but not to any third party, if the Report of the Directors contains errors as a result of recklessness or knowing misstatement or human life by enabling dishonest concealment of a material fact, but would not otherwise be liable. Report of the Directors people to do more, feel Pages 1-136 and 239-244 inclusive comprise the Report of the Directors that has been drawn up and presented in accordance with and in reliance upon English company law and the liabilities of the Directors in connection better and live longer. with that report shall be subject to the limitations and restrictions provided by such law. Website GlaxoSmithKline’s website www.gsk.com gives additional information on the Group. Notwithstanding the references we make in this Annual Report to GlaxoSmithKline’s website, none of the information made available on the website constitutes part of this Annual Report or shall be deemed to be incorporated by reference herein. Cautionary statement regarding forward-looking statements The Group’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document and written information released, or Front cover image oral statements made, to the public in the future by or on behalf of the Group, may contain forward-looking A child being seen by a doctor working for Brazil’s statements.
    [Show full text]